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Abstract
Background: We have investigated the role that the mutation rate and the structure of genetic variation at a locus play in
determining whether a gene is involved in disease. We predict that the mutation rate and its genetic diversity should be
higher in genes associated with disease, unless all genes that could cause disease have already been identified.
Results: Consistent with our predictions we find that genes associated with Mendelian and complex disease are
substantially longer than non-disease genes. However, we find that both Mendelian and complex disease genes are found
in regions of the genome with relatively low mutation rates, as inferred from intron divergence between humans and
chimpanzees, and they are predicted to have similar rates of non-synonymous mutation as other genes. Finally, we find that
disease genes are in regions of significantly elevated genetic diversity, even when variation in the rate of mutation is
controlled for. The effect is small nevertheless.
Conclusions: Our results suggest that gene length contributes to whether a gene is associated with disease. However, the
mutation rate and the genetic architecture of the locus appear to play only a minor role in determining whether a gene is
associated with disease.
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Introduction
Why do humans suffer from the diseases that we do? In part this
is clearly due to our anatomy and physiology, and that of the
organisms that infect us - we cannot have a disease of an organ
that we do not possess. But why do we suffer from cystic fibrosis
rather than some other disease of the lungs? One simple reason
might be variation in the mutation rate. Those genes and genomic
regions that have high mutation rates are more likely to generate
disease mutations, and hence be associated with a disease. The
rate of mutation of a locus will depend upon two factors: the rate
of mutation per site and the number of sites at which a mutation
can generate a disease phenotype. The per site mutation rate is
known to vary across the human genome at a number of different
scales such that some genes have mutation rates that are several
fold higher than other genes (reviewed in Hodgkinson et al. [1]).
Genes also vary considerably in their length, with some of the
largest, such as the dystrophin gene, being association with disease.
A more subtle factor affecting the likelihood of a gene being
associated with a disease is the genealogy. At each site in the
genome there is an underlying genealogy whereby every
chromosome in the population is related via a bifurcating tree to
every other chromosome at that site. If there is no recombination
between sites then sites share the same genealogy. The shape and
depth of the genealogy depends on several factors. The first is
chance; for example, the average total length of a genealogy for a
neutral locus in a population of stationary size is expected to be
proportional to 4N generations in a diploid species, where N is the
population size, but this is expected to have a variance of at least
(4N)2 generations [2]. Second, the genealogy depends on the
effective population size of the locus (Ne). Ne is thought to vary
across the human genome as a consequence of natural selection
[3,4]. Selection can reduce the Ne of a genomic region through
either a selective sweep caused by the passage of an advantageous
mutation through the population [5], or via background selection
caused by the removal of deleterious mutations [6]. Those regions
of the genome with low rates of recombination or a high density of
selected sites are expected to have low Ne, and this is expected to
reduce the genetic diversity of neutral and weakly selected variants
in these regions (reviewed in [7]). Analyses suggest that Ne varies
across the human genome by a few-fold [4]. The effective
population size is not expected to affect the frequency of
deleterious mutations in which the product of Ne and the strength
selection is greater than one. However, stochastic factors affecting
the genealogy are expected to be important irrespective of the
selection acting upon a mutation.
Previous analyses have shown that Mendelian disease genes are
30% longer than non-disease genes [8,9]. Comparative analyses
have also shown that genes associated with Mendelian diseases
have significantly, but only slightly higher rates of mutation per
site, as inferred from levels of synonymous divergence between
species [8,10]. The rather modest differences between disease and
non-diseases genes in the inferred mutation rate might be due to
time frame over which the mutation rate was inferred: Smith and
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Eyre-Walker [8] considered the divergence between human and
mouse, and Huang et al. [10] considered the divergence between
mouse and rat. This will give a poor estimate of the current
mutation rate at a locus in humans because the relative mutation
rate of a locus appears to have evolved through time [1,11]. The
mutation rate has also recently been predicted, based on a model
fitted to the locations of de novo mutations in humans, to be slightly
higher in disease associated genes [12], but the accuracy of this
model is unproven, and they consider the total mutation rate of the
exon, rather than the rate at non-synonymous sites. Here we
consider the divergence between humans and their most closely
related extant relative, chimpanzee, as our measure of the
mutation rate. We also consider whether the density of single
nucleotide polymorphism (SNP) is greater in disease than non-
disease genes.
Materials and Methods
To estimate mutation rate for each gene, we estimated their
intron divergence between the human and chimpanzee genomes
as follows. Alignments using the NCBI build 36 version of the
Figure 1. CDS length. (A) Mean total CDS length, and (B) Mean average CDS length. Total CDS length is the sum of all constitutive and alternately
spliced exons; average CDS length is the average CDS length of each transcript. Error bars represent the 95% confidence intervals.
doi:10.1371/journal.pone.0090166.g001
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human genome (hg18) and PanTro2 version of the chimp genome
were downloaded from the UCSC website (http://genome.ucsc.
edu/). Alignments were parsed into individual genic sequences
and realigned with MAFFT version 6 (http://mafft.cbrc.jp/
alignment/software/). Exon sequences were masked according
to exon annotation of the NCBI build 36 version of the human
genome from the ensemble database (http://www.ensembl.org/).
We did not correct for multiple hits; this is not necessary since the
average intron divergence between human and chimpanzee
sequences is 1.05% [13]. We calculated the rates of intron
Figure 2. Mutation rates. The mutation rate per site, as inferred from intron divergence between human and chimpanzee. A) Intron divergence
per site between human and chimpanzee; B) the predicted non-synonymous mutation rate per CDS site. Error bars represent the 95% confidence
intervals.
doi:10.1371/journal.pone.0090166.g002
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divergence for CpG and nonCpG sites separately since the former
have much higher rates of mutation. We used these intron
divergences to infer the rate of non-synonymous mutation in
human exons, by calculating the number of CpG and non-CpG
sites in each exon which when mutated would give a non-
synonymous change; in this calculation we assumed that all
mutations at CpGs are transitions, which is a good approximation
[14], and that 60% of mutations at other sites were transitions. If a
gene had multiple transcripts we made these calculations for each
transcript and averaged the result.
DNA sequence diversity data were taken from the 1000 genome
project [15].
Genes were designated as being associated with Mendelian
disease based upon the compilation made by Blekhman et al. [16].
Genes associated with genome-wide association studies (GWAS)
were obtained from the GWAS catalog (http://www.genome.gov/
gwastudies/); a gene in which the strongest GWAS signal was
found within the boundaries of a gene were designated as being a
GWAS gene.
To investigate what factors might influence patterns of genic
mutations, estimated by intron divergence, we considered a
number of variables. Intron GC content, nucleosome occupancy,
replication timing and male and female recombination rates were
downloaded from the UCSC website (http://genome.ucsc.edu/).
We used A365 values to study the influence of nucleosome
occupancy on the distribution of genic mutations rate across the
genome. Recombination rates per MB were from Kong et al [17].
Replication time data were from Chen et al. [18] and Hansen et al.
[19]. Qualitatively similar results were obtained using each of four
replication time datasets, so we only present the analysis using data
from an embryonic stem cell line BG02 [19]. Germ-line expression
data were from a study by McVicker and Green [20].
The dataset for this analysis is available as Table S1.
Results
We predict that unless all possible diseases with a genetic basis,
and all the genes that can cause them, have already been
discovered, then genes associated with diseases should have higher
genic mutation rates than non-disease genes, where the genic
mutation rate is determined by the product of gene length and the
mutation rate per site. We also predict that disease genes should be
in relatively diverse regions of the genome. To investigate these
predictions we compiled data from 17577 nuclear genes with
introns, of which 854 genes are known to cause a Mendelian
disease. We also analysed 1732 genes in which the strongest signal
in a genomic region in a genome wide association study (GWAS)
lay within the boundaries of the gene (i.e. all exons and introns
between the start and stop codon). The presence of an association
signal within the boundaries of the gene does not necessarily mean
that the causative mutation is within the protein coding sequence
or even within the boundaries of the gene, and many of these
associations may be in regulatory sequences [21]. We subsequently
excluded genes on the sex chromosomes since the Y-chromosome
is known to have a higher mutation rate and the X-chromosome a
lower mutation rate than the autosomes [22]. This yielded a
dataset of 17062 autosomal genes including 820 associated with a
Mendelian disease and 1726 with a GWAS signal. Details of the
dataset are given in Table S1.
Gene Length
Consistent with the hypothesis that disease genes should have
higher overall rates of mutation we find, as others have in the past
for genes causing Mendelian disease [8,9], that genes associated
with disease are significantly longer, in terms of their total coding
sequence (CDS) length (i.e. the sum of all constitutive and
alternatively spliced exons), than non-disease genes; Mendelian
disease genes are ,28% and GWAS genes ,44% longer than
non-disease genes (One-way ANOVA p,0.001) (Figure 1a). A
similar pattern is evident for average CDS length; both Mendelian
and GWAS disease genes are 50% longer than non-disease genes
(Figure 1b). The difference in average CDS length is greater than
in previous studies [8,9], but this is likely to be due to the
improvement in genome annotation; the average length of genes is
slightly shorter than in previous analyses.
Strikingly, the difference in length is as great or greater for the
GWAS than the Mendelian disease genes despite the fact that
many of the GWAS signals are likely to be outside the protein
coding sequence [21]. GWAS genes might have longer CDSs for
three reasons. First, genes with longer CDSs have a greater chance
of generating a disease mutation. Second, longer genes are more
likely to have a non-causative marker SNP in the CDS that is
associated with the disease. And finally since intron and total CDS
lengths are correlated (r = 0.36, p,0.001), genes with long CDSs
have longer introns and hence an increase chance of having
causative or non-causative SNPs in their introns. However, if we
control for the correlation between intron and CDS length by
regressing CDS length against intron length and taking the
residuals, we find that GWAS genes have longer CDSs, than non-
disease genes, even given their longer introns (t-test p,0.001;
Table 1. Standardised regression coefficients from multiple regressions.
Factor Intron Divergence
Predicted non-
synonymous mutation
rate Intron SNP density Average genealogy length
GC content 0.525*** 0.325*** 0.192*** 20.212***
Nucleosome occupancy –0.396*** –0.167*** –0.412*** –0.035
Female recombination rate –0.020* 0.018* 0.058*** 0.042***
Male recombination rate 0.202*** 0.143*** 0.129*** –0.048***
Germ-line expression –0.062*** –0.116*** –0.020* 0.032***
Replication time –0.132*** –0.157*** –0.071*** 0.038***
Distance to telomere –0.158*** –0.097*** –0.117*** 0.060***
Distance to centromere –0.018* –0.016 0.020* 0.014
Note that the replication time data is such that a negative slope indicates an increase in the variable through the cell cycle * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0090166.t001
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similar results are obtained if we regress log CDS length against
log intron length (p,0.001)). This suggests that GWAS genes are
not simply longer because they have longer introns; it therefore
seems that either GWAS genes are more likely to be associated
with disease because some causative mutations are within their
exons, or because there is a greater number of marker SNPs in
exons.
Mutation Rates
However, contrary to our expectations, we find that disease
genes are found in regions of the genome with significantly lower
per site mutation rates, as measured by intron divergence between
human and chimpanzee. The difference is highly significant (one-
way ANOVA p,0.001), but the difference is small with disease
genes having approximately 5% lower intron divergence than
non-disease genes (Figure 2a). The pattern differs between CpG
and non-CpG sites, with disease genes having lower divergence at
CpG sites and either similar or higher divergence at non-CpG sites
(results not shown). If we calculate the expected non-synonymous
mutation rate in the CDS by multiplying the proportion of non-
synonymous sites that are CpG and non-CpG in the CDS by the
respective levels of intron divergence, we still find that both
Mendelian and complex disease genes have slightly lower
mutation rates per site than non-disease genes (p = 0.004)
(Figure 2b). As expected, both Mendelian and complex disease
genes have significantly higher overall predicted rates of non-
synonymous mutation (p,0.001), driven by the fact that disease
genes have longer CDSs.
The fact that disease genes have lower predicted rates of non-
synonymous mutation per site is inconsistent with our hypothesis,
but this might be due to the fact that they have features which
predispose them to lower mutation rates - for example they might
be transcribed at lower levels and hence have lower rates of
mutation [23]. Divergence at intronic and intergenic sites is known
to be significantly correlated to a number of other variables
including GC-content [3,18,24,25], recombination rate
[3,24,26,27,28], replication time [18,29,30], distance to the
telomere and centromere [3,13,18,24], gene density [3,24],
nucleosome occupancy [11] and expression level [23]. We confirm
previous results and show that intron divergence is positive
correlated to GC content and male recombination rate within a
multiple regression; and that intron divergence is negatively
correlated to replication time (later genes have higher divergence),
distance to the telomere, distance to the centromere, female
recombination rate, nucleosome occupancy and germ-line expres-
sion (Table 1). Similar patterns are evident for the predicted non-
synonymous mutation rate (Table 1). If we take the residuals from
a multiple regression of intron divergence against all the genomic
variables above we find that intron divergence and the predicted
rate of non-synonymous mutation do not differ significantly
between disease and non-disease genes.
Genetic Diversity
Although, disease genes are found in regions of the genome with
relatively low rates of intron mutation we find that disease genes
have a significantly greater density of polymorphisms segregating
in their introns than non-disease genes; the difference is 11% and
17% for the Mendelian and GWAS genes respectively (Figure 3a).
If we divide the density of SNPs by the divergence of introns to
estimate a quantity that is proportional to the average length of the
genealogies at the locus, we find that Mendelian and GWAS genes
have significantly longer average genealogy lengths that are 9%
and 12% greater than non-disease genes (ANOVA p,0.001; t-test
of Mendelian versus non-disease p,0.001; t-test of GWAS versus
non-disease p,0.001). It is odd that the difference between disease
Figure 3. Diversity and genealogy estimates. The diversity in
disease and non-disease genes measured as the A) average intron SNP
density, B) the average intron SNP density divided by intron divergence,
C) and the mean minor allele frequency (MAF). Error bars represent the
95% confidence intervals.
doi:10.1371/journal.pone.0090166.g003
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and non-disease genes is less pronounced for average genealogy
length than diversity given that disease genes have lower intron
divergence than non-disease genes. This is probably due to non-
linearities associated with ratios.
Although, we find that disease genes have higher diversities and
average genealogy lengths than non-disease genes, we find no
evidence that the predicted non-synonymous population mutation
rate in the CDS (calculated as the proportion of non-synonymous
sites that are CpG multiplied by the SNP density at CpG sites in
introns plus the proportion of non-synonymous sites that are non-
CpG multiplied by the SNP density at non-CpG in introns) differs
between disease and non-disease genes. However, the calculation
of the predicted non-synonymous population mutation rate is
subject to considerable error because we have relatively few intron
CpG sites and SNP density is very low in humans.
It is possible that disease genes have higher diversities and
average genealogy lengths because disease genes have features that
predispose them to higher values, not because by having higher
values they are more likely to be associated with disease. We find
that intron SNP density is positively correlated to GC content,
female and male rates of recombination and distance to the
centromere and negatively correlated to the time of replication
(late genes have higher diversity), nucleosome occupancy, germ-
line expression and distance to the telomere (Table 1). If control
for these factors by taking the residuals from the multiple
regression we find that SNP density is still significantly greater in
both Mendelian and GWAS genes, than in non-disease genes
(ANOVA p,0.001; individual t-tests p,0.001). Likewise we find
the average genealogy length is positively correlated to all variables
except GC content, nucleosome occupancy and male recombina-
tion rate (Table 1), and that after controlling for these associations,
disease genes still have significantly greater average genealogy
lengths than non disease genes (ANOVA p=0.019; individual t-
tests Mendelian versus non-disease p= 0.21, GWAS versus non-
disease p= 0.001).
Although disease genes have a greater number of SNPs per bp
than non-disease genes the distribution of the genetic variation
varies in an inconsistent manner between categories of genes; the
average minor allele frequency is ,10% greater in Mendelian,
and ,10% lower in GWAS genes, than in non-disease genes
(ANOVA p,0.01) (Figure 3b).
Discussion
We have found that genes associated with disease are longer and
reside in regions of the genome with greater intron diversities and
average genealogy lengths than non-disease genes. This is
consistent with a role for mutation and genetic variation in
determining whether a gene becomes associated with disease.
However, we find no evidence that the mutation rate per site is
greater in disease than non-disease genes. Nevertheless, what is
ultimately important is the mutation rate of the gene, and we find
that the overall mutation rate of disease genes is greater than non-
disease genes because disease genes are longer (p,0.001). The
effect of gene length may be more conspicuous than for the other
variables, because there is substantially more variation in CDS
length per gene (coefficient of variation (CV) = 0.78) than in intron
divergence (CV=0.56), intron SNP density (CV=0.42) and
average genealogy length (CV=0.47); in reality the differences
in CV are even larger because intron divergence, and in particular
SNP density and average genealogy length, are likely to be subject
to large sampling error variances that CDS length is not.
We have interpreted the fact that disease genes are longer than
non-disease genes as evidence that genes with higher mutation
rates are more likely to generate disease mutations, however, it is
possible that disease genes are longer simply because genes
involved in particular processes that could cause disease to be
longer. It is difficult to test this hypothesis without knowing all the
genes that might cause disease. We have also interpreted the
greater diversity in disease genes as being what causes them to be
associated with disease. However, in the case of the complex
disease genes this might simply reflect a bias towards a better
ability to detect GWAS signals in regions of higher diversity.
Although, we have found that disease genes are longer than
non-disease genes, and that they have greater diversity and
average genealogy lengths, the differences are fairly small. It is
therefore evident that either most disease associated genes have
been discovered, which seems unlikely, or that the function of the
gene is far more important in determining whether a gene causes
disease than its effective mutation rate.
Supporting Information
Table S1 The data matrix used in the analysis. A
description of column headings is provided as a separate worksheet
within the Excel spreadsheet.
(XLSX)
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